Gastric administration of a commercial flavonoid inhibits in vivo and ex vivo platelet aggregation in dogs with stenosed coronary arteries

H. E. Osman, N. Maalej, J. D. Folts

Research output: Contribution to journalArticlepeer-review

2 Scopus citations

Abstract

Epidemiological studies have show an inverse relation between the intake of flavonoids (Fs) and death from coronary artery disease, explained in part by the inhibition of LDL cholesterol oxidation and also by reduced platelet aggregation (PA). We tested the effect of Fs found in a commercially available as French Para 'Dox (FPD) (Arkopharma Inc.) on ex vivo and in vivo PA. In eight dogs with mechanically injured and stenosed coronary arteries (SCA), cyclic flow reductions (CFRs) due to thrombus formation occurred at a rate of 8±3/30 min. The CFRs were abolished after 125±22 min of an intragastric dose of 20 mg/kg of FPD. Ex vivo PA induced by collagen was decreased by 38±11%. In five other dogs treated orally with FPD (10 mg/kg) for ten days, ex vivo PA was decreased 41± 10% (P<0.01) compared to control. After ten days of feeding, small CFRs occurred at a rate of 4 ±2/30 min but were abolished by 10 mg/kg dose of FPD. CFRs in the Folts model are abolished by aspirin, but are renewed by infusion of 0.2 μg/Kg/min of epinephrine (Epi). Infusing Epi did not renew CFRs in any of the dogs receiving FPD. FPD has Fs also found in wine including quercetin, catechin, which are known to inhibit PA and raise platelet cyclic GMP levels in vitro. FPD is possibly a better platelet inhibitor than aspirin since it protects against Epi induced coronary thrombosis, in part by elevating platelet cyclic GMP levels. FPD may prove to be a useful alternative dietary supplement to gain the potential health benefits of red wine without concomitant alcohol intake.

Original languageBritish English
Pages (from-to)A314
JournalFASEB Journal
Volume11
Issue number3
StatePublished - 1997

Fingerprint

Dive into the research topics of 'Gastric administration of a commercial flavonoid inhibits in vivo and ex vivo platelet aggregation in dogs with stenosed coronary arteries'. Together they form a unique fingerprint.

Cite this